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Abstract
Background: The development and regression of corpus luteum (CL) is characterized by
an intense angiogenesis and angioregression accompanied by luteal tissue and extracellular
matrix (ECM) remodelling. Vascular Endothelial Growth Factor (VEGF) is the main
regulator of angiogenesis, promoting endothelial cell mitosis and differentiation. After the
formation of neovascular tubes, the remodelling of ECM is essential for the correct
development of CL, particularly by the action of specific class of proteolytic enzymes known
as matrix metalloproteinases (MMPs). During luteal regression, characterized by an
apoptotic process and successively by an intense ECM and luteal degradation, the activation
of Ca++/Mg++-dependent endonucleases and MMPs activity are required. The levels of
expression and activity of VEGF, MMP-2 and -9, and Ca++/Mg++-dependent endonucleases
throughout the oestrous cycle and at pregnancy were analyzed.
Results: Different patterns of VEGF, MMPs and Ca++/Mg++-dependent endonuclease were
observed in swine CL during different luteal phases and at pregnancy. Immediately after
ovulation, the highest levels of VEGF mRNA/protein and MMP-9 activity were detected. On
days 5–14 after ovulation, VEGF expression and MMP-2 and -9 activities are at basal levels,
while Ca++/Mg++-dependent endonuclease levels increased significantly in relation to day 1.
Only at luteolysis (day 17), Ca++/Mg++-dependent endonuclease and MMP-2 spontaneous
activity increased significantly. At pregnancy, high levels of MMP-9 and VEGF were observed.
Conclusion: Our findings, obtained from a precisely controlled in vivo model of CL
development and regression, allow us to determine relationships among VEGF, MMPs and
endonucleases during angiogenesis and angioregression. Thus, CL provides a very
interesting model for studying factors involved in vascular remodelling.
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Background
The growth rate of corpora lutea (CL) immediately after
ovulation is 4- to 20-fold more intense than that of some
of the most malignant human tumours and is sustained
by the formation of new blood vessels from capillaries of
the theca interna compartment [1]. Actually, 85% of the
dividing cells in the primate corpus luteum during the
early luteal phase are endothelial cells [2]. The duration of
this intense angiogenic phase in the corpus luteum varies
among species, but appears to be completed by day 6 of
the luteal phase in primates when capillaries surround
almost all luteal cells and capillary dilation is evident [3].
Vascular Endothelial Growth Factor (VEGF) effect on
endothelial cells mitosis and differentiation is considered
fundamental in vascular bed development. We have pre-
viously determined the ability of swine granulosa and
theca cells of growing follicles as well as luteal cells to pro-
duce VEGF [4,5].
After the stimulation of endothelial cells mitosis for neo-
vascular tubes development, the remodelling of extracel-
lular matrix is necessary and different proteolytic enzymes
are involved [6]. The extracellular matrix (ECM) has
become recognized as a key regulatory component in cel-
lular physiology, providing an environment for cell
migration, division, differentiation, anchorage, and in
some cases, an ultimate fate between cell survival or cell
death [7]. The highly regulated control of ECM turnover
and homeostasis occurs, in part, by the action of a specific
class of proteolytic enzymes known as the matrix metallo-
proteinases (MMPs). The MMPs and their associated
endogenous inhibitors act in concert to control aspects of
reproductive function. In the ovary and uterus, the MMP
system has been postulated to regulate all the dynamic
structural changes that occur throughout the oestrous
cycle [8].
To allow repeated opportunities of fertilization, the dura-
tion of CL life is rigorously programmed, in fact, after a
first period of rapid growth the tissue becomes stably
organized and prepares to switch to the phenotype
required for its next apoptotic regression [9,10]. Five to
ten grams of luteal tissue growth and disappear at each
ovarian cycle (21 days in sow).
The switch between growth and regression is mainly regu-
lated by LH (luteinising hormone – luteotrophyn) and
PGF2α (prostaglandin F2α – luteolysin) and their recep-
tors balance as well as by cytokines, growth factors, apop-
tosis/oncogenes related factors and plasminogen
activator/matrix metalloproteinase activators and inhibi-
tors [10-12]. If fertilization has not occurred, or implanta-
tion was unsuccessful, or the pregnancy ends, luteolysis is
initiated whereby the CL rapidly loses its progesterone-
producing ability followed by degradation of luteal tissue
[13]. Luteal regression is thought to occur through apop-
totic [9,14] and proteolytic [15] mechanisms; however,
the molecular mechanisms underlining this event are not
well characterized [8,16]. Apoptosis requires a wide extra-
cellular matrix remodelling [17] as well as the action of a
Ca++/Mg++-dependent endonuclease, that is developmen-
tally regulated in rat luteal cell nuclei [18], leading to the
degradation of genomic DNA into discrete oligonucleo-
some fragments. Therefore angiogenesis and apoptosis
and their regulation in the CL play a fundamental role in
the maintenance of reproductive performances. Further-
more, the ovary is the unique organ where strictly regu-
lated tissue hyperplasia and regression take place in a
cyclic manner under physiological conditions.
This study was aimed at characterizing the temporal
expression pattern of VEGF, MMP-2, MMP-9 and Ca++/
Mg++-dependent endonuclease throughout the lifespan of
swine CL and investigating whether the expression levels
of those molecules are related to CL functional stage.
Results
CL functional stage assessment
Both luteal progesterone (P4) concentration and prostag-
landin F2α receptor (FPr) mRNA expression followed typ-
ical swine luteal phase patterns. P4 concentrations
increased gradually during the formation of CL, reaching
the highest level during the mid-late phase (days 10 and
14), and then declined significantly on day 17 (Fig 1A).
Similarly, FPr mRNA levels increased gradually to a
greater extent on day 14 (3.4-fold in relation to day 1, Fig
1B). At pregnancy, high levels of P4 and FPr mRNA (7.7-
fold increase in relation to day 1) were observed.
DNase activity assay
A regulated Ca++/Mg++-dependent endonuclease expres-
sion and activity were detected in swine CL. Fig 2A illus-
trates the Ca++/Mg++-dependent endonuclease activity
found in luteal nuclei obtained at days 1, 14 and 17. A
marked activity was obtained with both Ca++ and Mg++
whereas the addition of Zn++ inhibited almost completely
the enzyme activity.
The amount of activable DNase gradually increased dur-
ing the oestrous cycle, maintaining high at pregnancy.
Moreover, a high level of spontaneous apoptosis in the
control group (No Salt) at day 17 was also observed (Fig
2B).
VEGF content
Both VEGF mRNA and protein presented similar patterns
of expression throughout the oestrous cycle. The highest
values of VEGF were observed immediately after ovula-
tion, decreasing significantly at day 3, and remaining
unchanged during the mid-luteal phase. At day 17, a sec-BMC Developmental Biology 2006, 6:58 http://www.biomedcentral.com/1471-213X/6/58
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ond significant drop was observed. At pregnancy VEGF
mRNA and protein levels were intermediate between
those of day 1 and 3 (Fig 3).
MMPs activity assay
Three distinct bands of gelatinase activity corresponding
to latent MMP-9 (proMMP9), latent MMP-2 (proMMP2)
and active MMP-2 (actMMP2) were evidenced in the
swine CL (Fig 4A). Gelatinolytic activities for both latent
and active forms of MMP-2 were considered together for
the analysis. The activities of MMP-2 and MMP-9 changed
over the luteal phase. Constant levels of MMP-2 activity
were observed during CL formation, increasing signifi-
cantly in late (day 17) luteal phase (Fig 4B). In contrast,
MMP-9 activity peaked in the early (days 1–3) and late
(day 17) luteal phase, showing the lowest values in the
midluteal phase (days 10–14 – Fig 4C). At pregnancy,
basal levels of MMP-2 and high levels of MMP-9 were
observed.
Discussion
The CL is a transient endocrine gland, which is formed
from the remnants of an ovulated follicle [13]. During this
process, a capillary network invades from the theca tissues
into the granulosa layers through a dynamic angiogenesis
process such that after its formation, the CL is one of the
most vascularised organs in the body [16]. During VEGF
driven angiogenesis, microvascular endothelial cells pro-
duce gelatinases (MMP-2 and -9), which breach the
perivascular basement membrane and allow endothelial
cells to migrate outward through the extracellular space
[19-21]. MMPs are also involved, together with Ca++/
Mg++-dependent endonuclease, in apoptotic tissue
remodelling at luteolysis.
In this study, proteases with gelatinolytic activity that is
consistent with MMP-9 and MMP-2 family members [7]
were identified in CL collected during the oestrous cycle
and at pregnancy. The gradual increase of FPr mRNA
expression, peaking on day 14, together with the accumu-
lation of Ca++/Mg++-dependent endonuclease, confirms
the competence acquired by the luteal tissue around this
moment to rapidly react to PGF2α and to initiate the
regression. These characteristics are maintained in the
pregnant CL which is always sensible to PGF2α. Moreo-
ver, elevated concentrations of P4 at day 14 corroborate
the CL ability to sustain an eventual pregnancy.
Members of MMP-system may be involved in several of
the proteolytic events that take place in the ovary during
the reproductive cycle [16]. MMP-2 and MMP-9 have pre-
viously been detected by zymography in homogenates of
rat ovaries [22,23], and in CL of bovine [24], human [15],
primates [25], mouse [26], ovine [27] and swine [17]. The
main role proposed for MMPs concerns the tissue remod-
elling associated to luteolysis.
Our findings demonstrated the presence of MMP-2 and
MMP-9 in the corpus luteum during different ovarian
phases. MMP-2 activity was basal during early-mid luteal
phase and at pregnancy while was maximal during luteol-
ysis. MMP-2 plays a role in various tissue remodelling
processes, including trophoblast invasion [28] and
tumour cell motility [20]. However, a persistence of MMP-
2 activity throughout the CL formation supports sugges-
tions that tissue remodelling continues throughout CL
development and maintenance.
Concerning MMP-9 activity, high levels were observed
during early luteal phase, luteolysis and pregnancy. MMP-
9 is probably involved in the extensive tissue remodelling
that occurs during CL formation, when extracellular mate-
rial, composed primarily of follicular elements that repre-
sent a basement membrane-type ECM, is removed
[15,29]. This clearance may create a more hospitable or
P4 and FPr mRNA levels in swine CL during different luteal  phases and pregnancy Figure 1
P4 and FPr mRNA levels in swine CL during different luteal 
phases and pregnancy. A: Changes in P4 levels (mean ± SEM). 
B: Changes in FPr mRNA expression in relation to day 1; 
error bars represent the range of relative expression. The 
statistical analysis were based upon the mean of 5 CLs per 
animal (n = 4/time point). Different letters represent signifi-
cant differences (p < 0.05).
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A: Representative electrophoresis profile of low molecular weight DNA from CL at day 1, 14 and 17 Figure 2
A: Representative electrophoresis profile of low molecular weight DNA from CL at day 1, 14 and 17. Each lane contains 10ug 
of DNA extracted from luteal nuclei after treatment with different cations. B: Nuclease activity in swine CL nuclei during differ-
ent luteal phases and pregnancy. For each time point only No Salt (open bars) and Ca+++Mg++ (closed bars) samples were pre-
sented. Data represent means ± SEM of percentage of low molecular weight DNA (≤ 2000 bp). The statistical analysis were 
based upon the mean of 5 CLs per animal (n = 4/time point). Different capital and small letters represent significant differences 
(p < 0.05) for No Salt and Ca+++Mg++ groups, respectively.
MWM CL 1day CL 14day CL 17day
Ca++ ++ + + + +
Mg++ ++ + + + +
Zn++ + + +
2000bp
B
A
a
a
b
c c
c c
0
10
20
30
40
50
60
70
80
90
1 3 5 1 01 41 7 6 0
(pregnant)
Days after ovulation
%
l
o
w
 
M
W
 
D
N
A
No Salt Ca++ Mg++
A A A
A A
B
ABMC Developmental Biology 2006, 6:58 http://www.biomedcentral.com/1471-213X/6/58
Page 5 of 9
(page number not for citation purposes)
spacious environment for the subsequent rapid prolifera-
tion and intermingling of luteal cells [21,30] and develop-
ment of luteal ECM [31]. This hypothesis is supported by
the findings that it is the primary metalloproteinase
detected in follicles explants [32]. In addition, MMP-9 is
the major MMP secreted into the culture medium of
luteinised bovine [33] and human granulosa cells [34].
A different activity profiles for both MMP-2 and MMP-9
were also observed in human [15] and bovine [21] corpus
luteum. In the porcine CL, mRNA expression for MMP-2
and MMP-9 was low during early luteal period (days 6–8
of the oestrous cycle), increasing significantly during mid-
luteal period (days 9–11), and reaching the highest values
during the late luteal period (days 13–15) [17]. These
results agree well with ours, considering that the authors
did not studied the earliest period of oestrous cycle (days
1–5 after ovulation), period in which we verified major
alterations of MMP-9 activity.
In the early luteal phase, we also detected the highest lev-
els of VEGF. As expected, VEGF mRNA and protein were
detected during all days of the oestrous cycle and showed
similar pattern of expression. High levels were verified
immediately after ovulation, concomitantly with the
intense luteal vascular growth and CL formation. Thus
supporting the role of VEGF in the angiogenesis of the
newly formed CL. Changes of VEGF levels in CL during
the oestrous cycle have been reported also in other species
[35-39]. Those reports, in accord with our results, demon-
strate that the highest VEGF mRNA expression and VEGF
protein concentration are detected during the early luteal
phase, and are followed by a significant decrease of
expression during the mid and late luteal phases.
VEGF mRNA and protein levels in swine CL during different  luteal phases and pregnancy Figure 3
VEGF mRNA and protein levels in swine CL during different 
luteal phases and pregnancy. A: changes in VEGF mRNA 
expression in relation to day 1; error bars represent the 
range of relative expression. B: changes in VEGF content 
(mean ± SEM). The statistical analysis were based upon the 
mean of 5 CLs per animal (n = 4/time point). Different letters 
represent significant differences (p < 0.05).
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A: Representative gelatin substrate zymography gel showing 
gelatinase activity in swine CL during different luteal phases 
and pregnancy. B: Relative abundance of MMP-2 as deter-
mined by densitometric analysis expressed as means ± SEM. 
C: Relative abundance of MMP-9 as determined by densito-
metric analysis expressed as means ± SEM. The statistical 
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4/time point). Different letters represent significant differ-
ences (p < 0.05).
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Taken together, our results provide that in addition to
intense angiogenesis (characterized by maximal VEGF
concentration), elevated luteal gelatinases may contribute
to the extensive luteal ECM and tissue remodelling that
occurs as the postovulatory follicle is transformed into the
CL [15,21]. Many studies relative to neoplastic growth
well describe the interplay between VEGF and MMPs [40-
43]. Bergers et al. [44] demonstrated that MMP9 is able to
mobilize matrix attached VEGF isoforms and this action
results essential for the switch between vascular quies-
cence to angiogenesis during carcinogenesis. Another
study showed that VEGF regulated ovarian cancer inva-
sion through secretion and activation of MMPs [45].
After the CL is fully formed, steroidogenesis is maximal
during the midluteal period, and MMP activity and VEGF
concentration are at basal levels. Interestingly, we previ-
ously reported an increased expression of the less abun-
dant and matrix-attached VEGF splice variants (VEGF188
and VEGF182) as well as of the two VEGF receptors in this
moment [5]. In this phase, luteal tissue prepares itself to
the next step cumulating high levels of FPr and endonu-
clease making the tissue very sensitive to luteolytic stimu-
lus. With the onset of structural regression, the MMPs are
again called into action for the remodelling and removal
of the CL [7].
The elevated expression of VEGF associated to the pres-
ence of MMP-9 at pregnancy suggests that initial ang-
iogenic process during the early luteal phase may be
renewed in swine pregnant CL. Increased angiogenesis at
pregnancy in luteal tissue is controversial. Wulff et al. [46]
demonstrated that luteal rescue is associated with a sec-
ond wave of angiogenesis in human CL, while Rowe et al.
[47] stated that no pregnancy-induced angiogenesis take
place in marmoset CLs. Certainly, a stable and efficient
vascular bed are required for the endocrine function of
pregnant CL. Pauli et al. [48] reported that the administra-
tion of anti-VEGFR-2 antibody during the pre- and post-
implantation periods in rodents, disrupted maternal ovar-
ian function eliminating pre-existing luteal blood vessels.
Thus, VEGF/VEGFR-2 pathway is critical to maintain the
functionality of luteal blood vessels during pregnancy and
might also be involved in regulating vascular permeability
and P4 release into the bloodstream [49]. Therefore, the
increase in VEGF at pregnancy is not unexpected but the
increase in MMP-9 needs further clarifications. The differ-
ent profile of VEGF/MMP-9 expression observed between
fully formed (midluteal phase) and pregnant CLs should
be taken into account when physiological effects will be
monitored.
Conclusion
We have demonstrated that CL development and regres-
sion is a very useful model for studying VEGF/MMPs rela-
tionships. During the very early luteal phase, high MMPs
activities coupled with high VEGF levels drive the tissue to
an "angiogenic phenotype", allowing CL growth under
LH stimulus. In the late luteal phase, low VEGF and ele-
vated MMPs levels may play role in the apoptotic tissue
and ECM remodelling during structural luteolysis.
Methods
Animal model
Synchronized folliculogenesis was obtained in 28 prepu-
bertal Large White gilts (96 ± 2.13 Kg, mean ± SEM) by
administration of 1250 IU equine chorionic gonadotro-
pin (eCG; Folligon, Intervet, Holland) and 750 IU hCG
(Corulon, Intervet) 60 h later. In this model, ovulation
occurs around 42–44 h after hCG administration (day 0).
Four animals were artificially inseminated 40 h after hCG
administration and pregnancies were determined by
ultrasonography 35 days after. Ovaries were recovered by
surgical laparotomy on days 1, 3, 5, 10, 14 and 17 after
ovulation (n = 4 animals/time point) and at day 60 of
pregnancy. Animals were pre-anesthetized by using aza-
perone (240 mg/gilt; Stresnil, Janssen, Belgium) and atro-
pine sodium salt (2 mg/gilt; Industria Galenica Senese,
Italy), and maintained under thiopental sodium (1.5 g/
gilt; Pentothal Sodium; Gellini, Latina, Italy) anaesthesia.
Five CLs from each gilt, chosen totally random from both
ovaries, were isolated, cut in three parts with a razor blade
and employed to perform all the analysis.
One third was weighed and homogenized in PBS (0.1 g/
ml) on ice bath by an Ultra Turrax. The homogenate
obtained was processed as follows: 500 µl were centri-
fuged at 2000 × g for 10 min at 4°C and supernatant was
stored at -20°C until VEGF determination and the
remainder of the homogenate was kept frozen until pro-
gesterone (P4) measurement and MMPs activity evalua-
tion.
Total RNA was isolated from the second third of the CLs
with the Tri-Pure reagent (Roche Diagnostic GmBH, Man-
nheim, Germany) and stored at -80°C until VEGF and
Prostaglandin F2α receptor (FPr) mRNA levels quantifica-
tion. The last part of samples was immediately processed
for nuclei extraction and Ca++/Mg++-dependent endonu-
clease activity evaluation. All the sampling procedures
were executed within 2 hours from the surgical removal of
the ovaries.
All animals were housed and used according to EEC ani-
mal care guidelines. The experimental procedures had
been previously approved by the Ethical Committee of
Bologna University.BMC Developmental Biology 2006, 6:58 http://www.biomedcentral.com/1471-213X/6/58
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P4 assay
Aliquots of 20 µl from each homogenate CL were
extracted with 5 ml petroleum ether. After centrifugation,
ether was collected and dried under a N2 stream. Dried
ether extracts were resuspended in 1 ml phosphate buffer,
diluted 1:50 and aliquots of 50 µl were then assayed by a
validated RIA as previously described [9].
The sensitivity of the assay was 3.7 pg/tube. The intra- and
interassay coefficients of variation were 6.3 and 19.6%,
respectively. The results are expressed in ng/mg tissue.
RNA extraction and Real-time quantitative RT-PCR
Total RNA from CLs, homogenized in Tri-Pure reagent (50
mg/ml), was extracted according to manufacturer's
instructions (Roche Diagnostic GmBH, Mannheim, Ger-
many). Purified RNA was resuspended in RNase-free
water and quantified (A260 nm). One microgram of total
RNA was reverse-transcribed to cDNA using iScript cDNA
Synthesis Kit (Bio-RAD Laboratories Inc., CA, USA) in a
final volume of 20 µl, according to the manufacturer's
instruction. Transcription reactions without reverse tran-
scriptase were performed to control for an eventual DNA
contamination.
Swine primers were designed for VEGF, FPr and HPRT
(Hypoxanthine Guanine Phosphorybosyl Transferase),
using the Beacon Designer 3.0 Software (Premier Biosoft
International, Palo Alto, Ca, USA). Their sequences,
expected PCR product length and accession number are
shown in Table 1. Real-time quantitative PCR was per-
formed in the iCycler Thermal Cycler (Bio-RAD Laborato-
ries Inc., Hercules, CA, USA) using SYBR green I detection.
The following reaction components was prepared to the
indicated end-concentrations: 0.6 µM of each primer, 1X
IQ SYBR Green BioRad Supermix (Bio-RAD Laboratories
Inc.), 150 ng of cDNA and H2O nuclease free to a final
volume of 25 µl. All samples were performed in duplicate
for all genes. The two step real-time PCR protocol
employed was: initial denaturation for 3 min at 95°C, 40
cycles at 95°C for 15 sec and 60°C for 30 sec, followed by
a melting step with a slow heating from 55 to 95°C with
a rate of 0.05°C/s. The specificity of the amplified PCR
products was verified by analysis of the melting curve,
which is product-specific. The relative mRNA level was
determined as the PCR cycle number that crosses an arbi-
trarily placed signal threshold (Ct). The Ct value correlates
inversely with the amount of target mRNA in the sample.
The housekeeping gene HPRT was used to normalize the
amount of RNA. The relative changes in VEGF and FPr
expressions were examined using the ∆∆Ct method
described previously [50], with ∆Ct = Cttarget - CtHPRT and
∆∆Ct = ∆Ct(days 3,5,10,14,17,60) - ∆Ct(day 1). As PCR amplifica-
tion is an exponential process, a ∆∆Ct difference denotes
a shift in regulation by a factor of two (2-∆∆Ct).
Real-time efficiencies were acquired by amplification of a
standardised dilution series and corresponding slopes and
PCR efficiencies were calculated using iCycler iQ Real
Time PCR Detection System (Bio-Rad Laboratories Inc.).
Ca++/Mg++-dependent endonuclease activity assay
Tissues were immediately treated to isolate nuclei and to
determine endonuclease activity in the samples [51].
In brief, minced tissue was homogenized (1/10, w/v) with
a Dounce homogenizer in a homogenization solution
containing 10 mM Tris-Cl (pH 7.4), 3 mM MgCl2, 3 mM
EGTA, and 250 mM sucrose. The homogenate was filtered
and then centrifuged at 800 g for 15 min at 4°C. The
resulting pellet was resuspended in the homogenization
solution supplemented with 0.5% (v/v) nonidet P40,
incubated for 15 min at 4°C and then centrifuged at 800
g for 15 min at 4°C. The resulting pellet was resuspended
in a solution containing 10 mM Tris-Cl (pH 7.4), 25 mM
NaCl, and 340 mM sucrose. The reaction mixture for the
DNA fragmentation assay was performed with 30 mg of
luteal tissue and 1 mM Ca++ and 5 mM Mg++, with or with-
out the addition of 2 mM Zn++. A control reaction, with-
out salts, was also carried out. The reactions were
performed at 37°C for 10 min, after which low and high
molecular weight DNA were extracted; residual RNA was
removed by addition of RNase A. DNA content was eval-
uated by densitometric scanning under a UV transillumi-
nator after 2% agarose gel electrophoresis run. Low
Table 1: Sense and antisense primers sequences used for real time RT-PCR.
Primer Sequence (5'-3') Product size (bp)
HPRT sense GGACAGGACTGAACGGCTTG
HPRT antisense GTAATCCAGCAGGTCAGCAAAG 115
VEGF sense* CCTTGCCTTGCTGCTCTACC
VEGF antisense* CGTCCATGAACTTCACCACTTC 101
FPr sense TCAGCAGCACAGACAAGG
FPr antisense TTCACAGGCATCCAGATAATC 151
*VEGF primers were located on a common region for all VEGF isoforms.BMC Developmental Biology 2006, 6:58 http://www.biomedcentral.com/1471-213X/6/58
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molecular weight DNA (≤ 2000 bp) was expressed as per-
cent of total DNA in the sample.
VEGF assay
Luteal VEGF concentrations were measured in 100 µl sam-
ples of homogenate supernatants by a specific enzyme
linked immune-adsorbent assay (ELISA, Quantikine,
R&D Systems, Minneapolis, MN, USA) previously vali-
dated for the measurement of porcine VEGF [4]. This
highly specific sandwich assay recognizes VEGF164 as
well as VEGF120, while it exhibits negligible cross-reactiv-
ity with all cytokines/growth factors tested. A 96-well
plate reader (Biomek 1000, Beckman Instruments, Fuller-
ton, CA, USA) set to read at 450 nm emission was used to
quantify the results. The sensitivity of the assay was 5 pg/
ml, and the intra- and interassay coefficients of variation
were less than 6 and 10%, respectively. All data are
expressed as pg/mg protein; protein concentration was
determined according to Lowry method [52], using a pro-
tein assay kit (Sigma Diagnostics, St Louis, MO, USA).
MMPs activity assay
MMP-2 and -9 activities were analyzed by use of gelatin
zymography on 10% Tris-Glycine poliacrylamide pre-cast
gels with 0.1% gelatin (10% Novex Zymogram Gels, Inv-
itrogen U.K.). Aliquots containing 30 µg of total proteins,
mixed with an equal volume of sample buffer (Novex Tris-
Glycine SDS sample Buffer 2X, Invitrogen U.K.) were
loaded into the gel. Electrophoresis was performed under
non-reducing conditions at a constant voltage (125 V for
120 minutes). Following electrophoresis, gels were
washed for 30 minutes in Novex Zymogram Buffer (Invit-
rogen U.K.), equilibrated at room temperature for 30 min-
utes in developing buffer (Novexα Zymogram Developing
Buffer, Invitrogen U.K.) and then incubated at 37°C for
22–24 hours in fresh developing buffer. Band of gelatino-
lytic activity were developed after staining gels for 6–8
hours with Simply Blue Safe stain (Invitrogen U.K.) by
comparison with a MMP-2 and -9 human standard
(Chemicon International, CA, USA).
Gel images were captured with a computerized system
(Geldoc 1000, Bio-Rad), and gelatinolytic bands were
measured with densitometric analysis software (Quantity
One, Bio-Rad). The resulting data are expressed as arbi-
trary units (AU).
Statistical analysis
The statistical analysis were based upon the mean of 5 CLs
per animal (n = 4/time point), since no significant differ-
ences among CLs within the same animal were observed.
Differences in relative mRNA expression of VEGF and FPr
(using the ∆Ct values), VEGF protein levels, progesterone
contents and MMPs and Ca++/Mg++-dependent endonu-
clease activities were determined using one-way ANOVA
(SPSS Version 13.0, Inc, Chicago, IL, USA), followed by
the Duncan's post-hoc test. Data are presented as mean ±
SEM. A value of p < 0.05 was considered significant.
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